Blueprint Medicines (BPMC) Misses Q4 EPS by 12c, Miss on Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq climbs over 1% as SpaceX, Super Micro improve AI sentiment
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Nvidia’s Huang highlights AI benefits in Berlin speech amid wider European tour
- AI bubble about to burst? Not yet, Yardeni says
Tweet
Share
E-mailGet Alerts BPMC Hot Sheet
Join SI Premium – FREE
Note: EPS may not be comparable
Blueprint Medicines (NASDAQ: BPMC) reported Q4 EPS of ($1.23), $0.12 worse than the analyst estimate of ($1.11). Revenue for the quarter came in at $1.63 million versus the consensus estimate of $5.28 million.
For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Netflix shares fall over 5% premarket on soft current-quarter revenue guidance
- Barclays cuts Cirrus Logic price target to $95 from $130, cuts to Underweight
- Elevance Health Inc. (ELV) Tops Q3 EPS by $2.29, Beats on Revenue; Offers FY EPS Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
